【Objective】 To investigate the clinical characteristics of COVID-19 induced deaths and analyze the causes of death. 【Methods】 This was a hospital-based, retrospective, observational cohort study involving hospitalized patients diagnosed with COVID-19 in People’s Hospital of Wuhan University during January 27 and February 25, 2020. The clinical data of identified patients who had died of COVID-19 were retrieved and reviewed. We analyzed the death causes and compared the changes in laboratory findings between patients before death and early onset to summarize the inherent clinical characteristics. 【Results】 We recorded a total of 21 deaths, 61.9% of which had occurred due to simple respiratory failure, followed by respiratory failure with myocardial injury (19%), respiratory failure with renal failure (9.5%), and respiratory failure with shock (9.5%). At the late time, lab test data indicated that white blood cells, D-dimer, amino-terminal brain natriuretic peptide precursors, and hypersensitive C-reactive protein significantly increased while counts of lymphosyte significantly decreased (P<0.05). 【Conclusion】 Continuous monitoring of cardiac function, renal function, and infection severity can assess the disease progression accurately. Moreover, timely intervention has a positive effect in reducing COVID-19 mortality.

Objective: This study’s objective is to assess the efficacy and safety of Pulsed Magnetic Therapy System (PMTS) in improving insomnia disorder. Methods: Participants with insomnia disorder were randomly assigned to receive either PMTS or sham treatment for four weeks (n= 153; PMTS: 76, sham: 77). Primary outcomes are the Insomnia Severity Index (ISI) scores at week 0 (baseline), 1, 2, 3, 4 (treatment), and 5 (follow-up). Secondary outcomes are the Pittsburgh Sleep Quality Index at baseline and week 4, and weekly sleep diary-derived values for sleep latency, sleep efficiency, real sleep time, waking after sleep onset, and sleep duration. Results: The ISI scores of the PMTS group and the sham group were 7.13±0.50, 11.07±0.51 at week 4, respectively. There was a significant group×time interaction for ISI (F3.214, 485.271=24.25, p<0.001, ηp 2=0.138). Only the PMTS group experienced continuous improvement throughout the study; in contrast, the sham group only experienced a modest improvement after the first week of therapy. At the end of the treatment and one week after it, the response of the PMTS group were 69.7% (95% confidence interval [CI]: 58.6%–79.0%), 75.0% (95% CI: 64.1%–83.4%), respectively, which were higher than the response of the sham group (p<0.001). For each of the secondary outcomes, similar group×time interactions were discovered. The effects of the treatment persisted for at least a week. Conclusion PMTS is safe and effective in improving insomnia disorders.